Cover of the EUS 4th Edition Textbook
The Most Widely Read EUS Textbook

Dedicated to Education

The textbook, Endosonography, edited by Drs. Hawes, Fockens and Varadarajulu, is dedicated to EUS education and is the most widely read textbook on EUS in the world. The book also has an online component in which literature review is posted on a quarterly basis.

  • The 3rd edition of the textbook was awarded the first prize by the British Medical Journal in internal medicine category in 2016
  • 4th edition of the textbook was released in August at the Endoscopy Live 2018 conference.
Research at The Center for Interventional Endoscopy

Active Clinical Trials

20 items. To interact with these items, press Control-Option-Shift-Right Arrow
Lipidomics, Proteomics and Volatile Organic Compounds Biomarkers in Bile and Serum

Project ID: 649074

Tag Name: AdventHealth sponsored prospective

PI Name: Navaneethan, Udayakumar

Sponsor: AdventHealth

Primary Aim
To identify and evaluate proteomics, lipidomics, micro-RNAs and VOCs changes in blood and bile that may give specific indications of malignant cell metabolism in cancer. By extensive characterization of these tumor-specific changes, we aim to determine their usefulness as biomarkers in the early diagnosis of cancer.

EUS-Guided pancreatic cyst ablation: A Registry

Project ID: 723324

Tag Name: AdventHealth sponsored prospective

PI Name: Varadarajulu, Shyam

Sponsor: AdventHealth

Primary Aim:
To maintain data on all patients undergoing EUS-guided ablation of pancreatic cysts using paclitaxel and gemcitabine and to assess its treatment efficacy. This will enable us to evaluate our treatment regimen and improve our clinical performance.

A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)

Project ID: 787598

Tag Name: Industry Sponsored Other

PI Name: Navaneethan, Udayakumar

Sponsor: AbbVie

Primary Aim:
To evaluate the long-term safety of HUMIRA® in moderately to severely active UC adult patients who are treated as recommended in the local product label. The long-term safety of patients being prescribed and treated with IMM (6-MP or AZA) with no concurrent biologic use will also be evaluated.

Stent vs Indomethacin for Preventing Post-ERCP Pancreatitis

Stent vs Indomethacin for Preventing Post-ERCP Pancreatitis: The SVI Trial - A Multicenter Randomized Non-inferiority Clinical Trial of Rectal Indomethacin Alone vs. Indomethacin & Prophylactic Pancreatic Stent Placement for Preventing Post-ERCP Pancreatitis in High-Risk Cases

Project ID: 793496

Tag Name: NIH-Funded

PI Name: Varadarajulu, Shyam

Sponsor: Medical University of South Carolina

Primary Aim:
To assess whether rectal indomethacin alone is non-inferior by a pre-specified amount therapeutic effect to the combination of rectal indomethacin and prophylactic pancreatic stent placement (PSP) for preventing post-ERCP pancreatitis (PEP) in high-risk cases.

Entyvio (vedolizumab) long-term safety study

Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with Ulcerative Colitis or Crohn’s Disease.

Project ID: 836311

Tag Name: Industry Sponsored Drug

PI Name: Navaneethan, Udayakumar

Sponsor: Takeda

Primary Aim:
To assess the long-term safety of vedolizumab versus other biologic agents in patients with UC or CD.

Vedolizumab 4006 (EXPLORER)

Vedolizumab 4006 (EXPLORER): An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with Vedolizumab, IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn’s Disease Stratified at Higher Risk for Developing Complications

Project ID: 905177

Tag Name: Industry Sponsored Drug

PI Name: Navaneethan, Udayakumar

Sponsor: Takeda

Primary Aim:
To determine the effect of triple combination therapy with an anti-integrin (vedolizumab IV), a TNF antagonist (adalimumab SC), and an immunomodulator (oral methotrexate) on endoscopic remission at Week 26.

Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn’s Disease

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn’s Disease

Project ID: 916558

Tag Name: Industry Sponsored Drug

PI Name: Navaneethan, Udayakumar

Sponsor: Janssen Research & Development

Primary Aim:
To evaluate the efficacy of JNJ-64304500 to reduce the CDAI score from baseline. To evaluate the safety of JNJ-64304500.

Randomized trial examining the impact of pancreatic duct stent placement in patients with acute necrotizing pancreatitis in the prevention of walled-off necrosis

Project ID: 922733

AdventHealth sponsored prospective

PI Name: Varadarajulu, Shyam

Sponsor: AdventHealth

Primary Aim:
To compare the incidence of WON between the PD stent and no PD stent groups at 4-6 weeks post-index ERCP.

A Phase 4 Open-Label-Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Non-responders With Moderately to Severely Active Ulcerative Colitis

Project ID: 979278

Tag Name: Industry Sponsored Drug

PI Name: Navaneethan, Udayakumar

Sponsor: Takeda

Primary Name:
To determine the effect of vedolizumab IV dose optimization on mucosal healing compared with the standard vedolizumab IV dosing regimen at Week 30 in subjects with UC and high vedolizumab clearance, based on a predefined Week 5 serum vedolizumab concentration threshold and who are Week 6 nonresponders.

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD)

Project ID: 1080962

Tag Name: Industry Sponsored Drug

PI Name: Navaneethan, Udayakumar

Sponsor: Gilead

Primary Aim:
To evaluate the efficacy of filgotinib, when compared to placebo, in establishing clinical remission at Week 24.

Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Subject with Moderately to Severely Active Crohn’s Disease

A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Subject with Moderately to Severely Active Crohn’s Disease

Project ID: 1105697

Tag Name: Industry Sponsored Drug

PI Name: Navaneethan, Udayakumar

Sponsor: Janssen Research & Development

Primary Aim:
To evaluate the clinical efficacy of guselkumab in participants with Crohn’s disease; To evaluate the safety of guselkumab.

Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 Induction Therapy in patients with moderate-to-severely active ulcerative colitis who have failed previous biologics therapy

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 Induction Therapy in patients with moderate-to-severely active ulcerative colitis who have failed previous biologics therapy

Project ID: 1115140

Tag Name: Industry Sponsored Drug

PI Name: Navaneethan, Udayakumar

Sponsor: Boehringer Ingleheim

Primary Aim:
To prove the concept of clinical activity of BI 655130 in patients with moderate-to severely active ulcerative colitis who have failed previous biologic treatments and to identify efficacious and safe dose regimens in Part 1 (Phase II); To confirm efficacy and safety of BI 655130 in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments in Part 2 (Phase III).

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn’s Disease

Project ID: 1122883

Tag Name: Industry Sponsored Drug

PI Name: Navaneethan, Udayakumar

Sponsor: Gilead

Primary Aim:
To measure the proportion of subjects establishing combined fistula response at Week 24.

Endoscopic resection of large colorectal polyps: An observational cohort study (Large Polyp Study group, study III)

Project ID: 1170706

Tag Name: VA

PI Name: Hasan, Muhammad

Sponsor: VA

Primary Aim:
To examine the rate of complications, complete polyp resection, and polyp recurrence during 5 years of follow-up.

Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease

GS-US-419-3895: A Phase 3, Double-blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease

Project ID: 1180293

Tag Name: Industry Sponsored Drug

PI Name: Navaneethan, Udayakumar

Sponsor: Gilead

Primary Aim:
To evaluate the efficacy of filgotinib as compared to placebo in establishing clinical remission by PRO2 at Week 10.

Evaluating the Safety and Efficacy of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis

GS-US-418-3898: A Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis

Project ID: 1180315

Tag Name: Industry Sponsored Drug

PI Name: Navaneethan, Udayakumar

Sponsor: Gilead

To evaluate the efficacy of filgotinib as compared to placebo in establishing EBS remission at Week 10.

Results of ERCP in Sphincter of Oddi Dysfunction: The RESPOND Study

Project ID: 1180708

Tag Name: NIH-Funded

PI Name: Varadarajulu, Shyam

Sponsor: NIDDK

Primary Aim:
To measure the patient-reported benefit of ERCP (level of improvement since the procedure) using the 12-month Patient Global Impression of Change. This metric will be compared to additional patient-centered outcomes, using validated instruments for pain, self-perceived quality of life, and pain-related disability.

Study to Evaluate the Safety and Effectiveness of Duodenal Mucosal Resurfacing Using the Revita™ System in the Treatment of Type 2 Diabetes

Randomized, Double-Blind, Sham-Controlled, Prospective, Multi-Center Pilot Study to Evaluate the Safety and Effectiveness of Duodenal Mucosal Resurfacing Using the Revita™ System in the Treatment of Type 2 Diabetes

Project ID: 1301446

Tag Name: Industry Sponsored Device

PI Name: Smith, Steve; Hawes, Robert

Sponsor: Fractyl

Primary Aim:
"To assess the safety of the Fractyl Revita™ System for the treatment of subjects with T2D suboptimally controlled on 2 oral antidiabetic medications; to assess the effect of DMR versus Sham procedures on glycemic endpoints 24 weeks after the procedure; to assess the effect of DMR on glycemic endpoints 48 weeks after the randomized procedure for durability of effect determination."

Endoscopic ultrasound guided liver biopsy using a 19-gauge Fine Needle Biopsy needle

Project ID: 1354057

Tag Name: AdventHealth sponsored prospective

PI Name: Hasan, Muhammad

Sponsor: AdventHealth

Primary Aim:
To determine the diagnostic adequacy of the liver biopsy specimen by obtaining a histological specimen using a 19 gauge caliber FNB needle.

EUS APP Logo

The EUS App

The EUS App covers everything that you need to effectively perform diagnostic and therapeutic EUS. The App is useful for both beginners who desire to learn the basics of EUS and advanced endoscopists wanting to learn cutting edge techniques.

Works with both Android and iPad Tablet Devices too.

Download for iPhone

Download for Android